Synthesis, Characterization, Crystal and Molecular Structure Studies
References
149
[1] Verweij, J., & Jonge, M. J. A. (2000). Achievements and future of chemotherapy. Eur. J. Cancer,
36, 1479–1487.
[2] Verdecchia, A. et al. (2001). Incidence and prevalence of all cancerous diseases in Italy: trends
and implications. Eur. J. Cancer, 37, 1149–1157.
[3] Garret, M. D., & Workman, P. (1999). Discovering novel chemotherapeutic drugs for the third
millennium. Eur. J. Cancer, 35, 2010–2030.
[4] Mencher, S. K., & Wang, L. G. (2005). Promiscuous drugs compared to selective drugs (promis-
cuity can be a virtue). BMC Clin. Pharmacol., 5, 3.
[5] Jimeno, A. J., & Hidalgo, M. (2006). Multitargeted therapy: can promiscuity be praised in an
era of political correctness? Crit. Rev. Oncol. Hematol., 59, 150–158.
[6] Colapret, J. A., Diamantidis, G., & Spencer, H. K. (1989). Synthesis and pharmacological
evaluation of 4,4-disubstituted piperidines. J. Med. Chem., 32, 968–974.
[7] Klockgether, T., Wullner, U., Steinbach, J. P., Petersen, V., Turski, L., & Loschmann, P. A.
(1996). Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur.
J. Pharmacol., 301, 67–73.
[8] Stephen, R. F. et al. (2002). 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable
5-HT(2A) receptor antagonists. J. Med. Chem., 45(2), 492–503.
[9] Christopher, A. W. et al. (2001). Combinatorial synthesis of CCR5 antagonists. Bioorg. Med.
Chem. Lett., 11, 3137–3141.
[10] Lihu, Y. et al.
(1998). 1- [2(R)-(2-amino-2-methylpropionyl amino)-3-(1H-indol-3-
yl)propionyl]-3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally
bioavailable, and short-duration growth hormone secretagogue. J. Med. Chem.,41(14),
2439–2441.
[11] Ramalingan, C., Balasubramanian, S., Kabilan, S., & Vasudevan, M. (2003). Synthesis
and microbiological evaluation of spiro piperidinyl heterocycles. Med. Chem. Res., 12(1),
41–44.
[12] Ramalingan, C., Balasubramanian, S., Kabilan, S., & Vasudevan, M. (2004). Synthesis and
study of antibacterial and antifungal activities of novel 1-[2-(benzoxazol-2-yl)ethoxy]-2,6-
diarylpiperidin-4-ones. Eur. J.Med. Chem., 39(6), 527–533.
[13] Amat, M., Hidalgo, J., & Bosch, J. (1996). Corrigendum. Tetra. Asym., 7, 1845.
[14] Jean-Marie, C., Isabelle, P., Wolfgang, S., Yveline, M., & Rival Camille, G. W. (2001). De-
sign, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-
yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors. J. Med. Chem., 44,
2707–2718.
[15] Maniyan, P. et al. (2006). Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide,
and urea derivatives of a dispiro-1,2,4-trioxolane piperidine. Bioorg. Med. Chem. Lett., 16,
5542–5545.
[16] Reddy, P. A. et al. (1997). Synthesis and anticonvulsant activities of 3,3- dialkyl- and 3-alkyl-
3-benzyl-2-piperidinones (delta-valerolactams) and hexahydro-2H-azepin-2-ones (epsilon-
caprolactams). J. Med. Chem., 40, 44–49.
[17] Matthew, W. H., Reddy, P. A., Douglas, F. C., & Steven, M. R. (1998). Inhibition of voltage-
dependent sodium channels by the anticonvulsant α-aminobutyric acid type A receptor modu-
lator, 3-benzyl-3-ethyl-2-piperidinone. J. Pharmacol. Exp. Ther., 285, 1303–1309.
[18] Kirk, K. L., & Filler, R. (1996). In Biomedical Frontiers of Fluorine Chemistry, Symposium
Series, American Chemical Society: Washington DC, 639, 1–9.
[19] Gelders, Y. G., Heylen, S. L. E., Vander, B. G., Reyntjens, A. J. M., & Janssen, P. A. J. (1990).
Pilot Clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsy-
chiatry, 23, 206–211.
[20] Otwinowski, Z., & Minor, W. (1997). Macromolecular Crystallography 276 part A Carter Jr,
C. M., Sweet, R. M. (Eds.), Academic Press: New York, 307.